Free Trial

Roivant Sciences (ROIV) Competitors

Roivant Sciences logo
$11.62 +0.33 (+2.92%)
As of 04:00 PM Eastern

ROIV vs. BNTX, ONC, SMMT, TEVA, ITCI, GMAB, RDY, ASND, MRNA, and VTRS

Should you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include BioNTech (BNTX), Beigene (ONC), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

Roivant Sciences vs.

BioNTech (NASDAQ:BNTX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership.

BioNTech received 90 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.57% of users gave Roivant Sciences an outperform vote while only 46.93% of users gave BioNTech an outperform vote.

CompanyUnderperformOutperform
BioNTechOutperform Votes
145
46.93%
Underperform Votes
164
53.07%
Roivant SciencesOutperform Votes
55
78.57%
Underperform Votes
15
21.43%

BioNTech has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BioNTech has a net margin of -15.16% compared to Roivant Sciences' net margin of -119.54%. BioNTech's return on equity of -2.35% beat Roivant Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
BioNTech-15.16% -2.35% -2.05%
Roivant Sciences -119.54%-14.05%-12.81%

Roivant Sciences has lower revenue, but higher earnings than BioNTech. Roivant Sciences is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNTech$2.75B8.99$1.01B-$3.00-34.35
Roivant Sciences$122.59M66.53$4.35B-$0.15-76.19

BioNTech presently has a consensus target price of $143.44, indicating a potential upside of 39.19%. Roivant Sciences has a consensus target price of $17.50, indicating a potential upside of 53.12%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than BioNTech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNTech
0 Sell rating(s)
3 Hold rating(s)
14 Buy rating(s)
1 Strong Buy rating(s)
2.89
Roivant Sciences
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, BioNTech had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 22 mentions for BioNTech and 17 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.35 beat BioNTech's score of 0.93 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioNTech
9 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Roivant Sciences
13 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

BioNTech and Roivant Sciences tied by winning 9 of the 18 factors compared between the two stocks.

Get Roivant Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ROIV vs. The Competition

MetricRoivant SciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$8.16B$6.83B$5.52B$7.70B
Dividend YieldN/A3.09%5.11%4.22%
P/E Ratio-76.237.3122.3418.30
Price / Sales66.53239.14391.19102.96
Price / CashN/A65.8538.1834.62
Price / Book1.476.416.674.19
Net Income$4.35B$142.94M$3.22B$248.05M
7 Day Performance6.42%1.97%1.93%2.10%
1 Month Performance10.11%-1.51%-1.23%0.63%
1 Year Performance4.85%1.54%17.23%4.57%

Roivant Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ROIV
Roivant Sciences
2.1639 of 5 stars
$11.62
+2.9%
$17.50
+50.6%
+1.4%$8.29B$122.59M-77.46860Positive News
BNTX
BioNTech
2.379 of 5 stars
$101.81
+3.1%
$143.44
+40.9%
+18.2%$24.43B$2.75B-48.483,080Upcoming Earnings
ONC
Beigene
2.341 of 5 stars
$229.22
-0.8%
$316.71
+38.2%
N/A$22.66B$3.81B-27.829,000Analyst Forecast
Analyst Revision
Gap Up
SMMT
Summit Therapeutics
2.6628 of 5 stars
$25.22
+2.5%
$35.40
+40.4%
+508.8%$18.60B$700,000.00-90.07110Upcoming Earnings
Analyst Forecast
Gap Down
TEVA
Teva Pharmaceutical Industries
3.2593 of 5 stars
$13.30
-2.6%
$23.43
+76.2%
+10.5%$15.08B$16.54B-9.1736,800Upcoming Earnings
Analyst Revision
Positive News
ITCI
Intra-Cellular Therapies
0.8805 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560Upcoming Earnings
Analyst Forecast
GMAB
Genmab A/S
4.445 of 5 stars
$20.07
+0.1%
$39.17
+95.2%
-27.2%$13.28B$21.53B11.531,660Analyst Revision
RDY
Dr. Reddy's Laboratories
1.8477 of 5 stars
$13.68
+0.1%
$17.00
+24.3%
-6.4%$11.42B$311.31B21.7824,800Upcoming Earnings
ASND
Ascendis Pharma A/S
2.3354 of 5 stars
$161.15
-2.4%
$204.67
+27.0%
+18.9%$9.83B$363.64M-22.70640Upcoming Earnings
Positive News
MRNA
Moderna
4.337 of 5 stars
$25.13
+1.7%
$58.70
+133.6%
-75.1%$9.72B$3.20B-2.713,900Upcoming Earnings
Gap Down
VTRS
Viatris
1.8417 of 5 stars
$7.57
+0.1%
$10.50
+38.7%
-29.2%$9.04B$14.74B-10.2337,000

Related Companies and Tools


This page (NASDAQ:ROIV) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners